Citius Oncology, Inc. (NASDAQ:CTOR - Get Free Report) shares traded up 39.8% during trading on Monday . The company traded as high as $1.17 and last traded at $0.93. 70,080,356 shares changed hands during trading, an increase of 5,249% from the average session volume of 1,310,223 shares. The stock had previously closed at $0.67.
Citius Oncology Trading Down 2.4 %
The business's 50 day moving average is $1.00 and its two-hundred day moving average is $1.12. The company has a current ratio of 0.34, a quick ratio of 0.08 and a debt-to-equity ratio of 0.08.
Citius Oncology (NASDAQ:CTOR - Get Free Report) last released its quarterly earnings results on Friday, February 14th. The company reported ($0.09) EPS for the quarter.
Institutional Inflows and Outflows
A hedge fund recently raised its stake in Citius Oncology stock. IFP Advisors Inc lifted its holdings in Citius Oncology, Inc. (NASDAQ:CTOR - Free Report) by 173.1% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 22,215 shares of the company's stock after purchasing an additional 14,080 shares during the period. IFP Advisors Inc's holdings in Citius Oncology were worth $26,000 at the end of the most recent reporting period. 70.52% of the stock is owned by institutional investors and hedge funds.
About Citius Oncology
(
Get Free Report)
Citius Oncology, Inc is a pharmaceutical company, which engages in developing and commercializing targeted oncology therapies. Its lead product candidate is LYMPHIR, an engineered IL-2 diphtheria toxin fusion protein, for the treatment of patients with persistent or recurrent CTCL, a rare form of non-Hodgkin lymphoma.
Recommended Stories
Before you consider Citius Oncology, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Citius Oncology wasn't on the list.
While Citius Oncology currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
